Literature DB >> 18223325

Anterior-predominant prostatic tumors: zone of origin and pathologic outcomes at radical prostatectomy.

Hikmat A Al-Ahmadie1, Satish K Tickoo, Semra Olgac, Anuradha Gopalan, Peter T Scardino, Victor E Reuter, Samson W Fine.   

Abstract

Aggressive screening and prostate needle biopsy protocols have been successful in early detection of low-volume posterior tumors. Consequently, we have observed an increased incidence of anterior-predominant prostate cancers. However, the zones of origin, patterns of spread, and patterns of extraprostatic extension of this group of tumors have not been well studied. Of 1312 radical prostatectomies performed at our institution over a span of 4.5 years, 197 had predominant (largest) tumors anterior to the urethra in whole-mounted radical prostatectomy specimens. Detailed histopathologic analysis of this cohort was undertaken emphasizing the variability in anterior prostatic anatomy from apex through base to determine zone of origin and pathologic staging. Using this approach, 97/197 (49.2%) anterior-predominant tumors (ATs) were assigned to the anterior peripheral zone (APZ), 70 (35.5%) to the transition zone (TZ), 16 (8.1%) were of indeterminate zone, and 14 (7.1%) were of both zones. Comparing APZ and TZ tumors, there were no significant differences in Gleason scores, incidence of extraprostatic extension, overall surgical margin positivity rate, or laterality. Involvement of the anterior fibromuscular stroma was significantly more likely in tumors of TZ origin (P< or =0.01), yet was observed in 50.5% of APZ tumors. Conversely, APZ tumors were more commonly localized within the apical one third of the prostate. Most of the prostates (91.4%) also showed additional PZ tumors, which were occasionally stage determining (7/197; 3.9%). In conclusion, ATs of APZ origin are more prevalent than those arising from the TZ. Contrary to previous reports comparing TZ tumors to all PZ tumors, ATs of both zones exhibit similar grading and staging parameters in this series. Given these similarities, long-term clinical outcomes and future molecular analyses will be necessary to assess whether true differences in biology and behavior exist between tumors of TZ and APZ origin.

Entities:  

Mesh:

Year:  2008        PMID: 18223325     DOI: 10.1097/PAS.0b013e31812f7b27

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  30 in total

1.  Usefulness of perflubutane microbubble-enhanced ultrasound in imaging and detection of prostate cancer: phase II multicenter clinical trial.

Authors:  Hiroji Uemura; Futoshi Sano; Akira Nomiya; Toshihiro Yamamoto; Masafumi Nakamura; Yasuhide Miyoshi; Kenta Miki; Kazumi Noguchi; Shin Egawa; Yukio Homma; Yoshinobu Kubota
Journal:  World J Urol       Date:  2012-02-04       Impact factor: 4.226

2.  Incremental value of transition zone and midline apical biopsy at baseline TRUS-guided biopsy for prostate cancer detection.

Authors:  D M Somford; W Vreuls; T S Jansen; J P van Basten; H Vergunst
Journal:  World J Urol       Date:  2013-07-20       Impact factor: 4.226

3.  Investigation of 90Y-avidin for prostate cancer brachytherapy: a dosimetric model for a phase I-II clinical study.

Authors:  Francesca Botta; Marta Cremonesi; Mahila E Ferrari; Ernesto Amato; Francesco Guerriero; Andrea Vavassori; Anna Sarnelli; Stefano Severi; Guido Pedroli; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-03       Impact factor: 9.236

4.  MRI-directed cognitive fusion-guided biopsy of the anterior prostate tumors.

Authors:  Ian G Murphy; Elaine NiMhurchu; Robert G Gibney; Colm J McMahon
Journal:  Diagn Interv Radiol       Date:  2017 Mar-Apr       Impact factor: 2.630

5.  Hematoma in Retzius' space following US-guided prostate biopsy: evidence of the diagnostic accuracy using transrectal end-fire probe in the anterior prostate gland.

Authors:  Lucio Dell'atti
Journal:  J Ultrasound       Date:  2014-01-09

6.  Anterior gland focal cryoablation: proof-of-concept primary prostate cancer treatment in select men with localized anterior cancers detected by multi-parametric magnetic resonance imaging.

Authors:  Christina Sze; Efrat Tsivian; Kae Jack Tay; Ariel A Schulman; Leah G Davis; Rajan T Gupta; Thomas J Polascik
Journal:  BMC Urol       Date:  2019-12-05       Impact factor: 2.264

7.  Do prostatic transition zone tumors have a distinct morphology?

Authors:  Joaquin J Garcia; Hikmat A Al-Ahmadie; Anuradha Gopalan; Satish K Tickoo; Peter T Scardino; Victor E Reuter; Samson W Fine
Journal:  Am J Surg Pathol       Date:  2008-11       Impact factor: 6.394

8.  TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry.

Authors:  Anuradha Gopalan; Margaret A Leversha; Maria E Dudas; Alexandra C Maschino; Jeremy Chang; Hikmat A Al-Ahmadie; Ying-Bei Chen; Satish K Tickoo; Victor E Reuter; Samson W Fine
Journal:  Histopathology       Date:  2013-05-23       Impact factor: 5.087

Review 9.  Targeted Anterior Gland Focal Therapy-a Novel Treatment Option for a Better Defined Disease.

Authors:  Kae Jack Tay; Arnauld Villers; Thomas J Polascik
Journal:  Curr Urol Rep       Date:  2016-10       Impact factor: 3.092

10.  Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails.

Authors:  Amy S Duffield; Thomas K Lee; Hiroshi Miyamoto; H Ballantine Carter; Jonathan I Epstein
Journal:  J Urol       Date:  2009-09-16       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.